1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62152765CD6EF12B48525846D003E4390
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-patient-advocacy-2020-optimizing-structure-function-united-states?opendocument
18
19opendocument
2018.205.176.85
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Marketing Management Patient Advocacy

Patient Advocacy 2020: Optimizing Structure of the Advocacy Function in the United States

ID: 5576


Features:

17 Info Graphics

8 Data Graphics

45+ Metrics

15+ Narratives


Pages/Slides: 32


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Patient Advocacy 2020: Optimizing Structure of the Advocacy Function in the United States”

STUDY OVERVIEW

As treatment options become more complex and plentiful in the United States, pharmaceutical organizations are increasingly relying on their relationships with patient advocacy groups to educate and inform patients about new therapies and treatment options. During the same period that advocacy groups have risen in importance, pharma has been shifting its structural approach to maximize the efficiency of its interactions with external patient groups.

Best Practices, LLC conducted this benchmarking research to examine the ideal structures, skill sets, and staffing for pharma organizations that deal with advocacy groups in the United States. This study also identifies the preferred communication channels for patient advocacy groups.

KEY TOPICS

  • Understanding the advocacy landscape
  • Preferred advocacy structures
  • Communicating with advocacy groups
  • Profiling advocacy group experience & expertise

KEY METRICS
  • How would you describe the structure of your company’s patient advocacy function?Do you feel the current structure of your patient advocacy function is appropriate for your organization?
  • How does your company ensure that patient advocacy organizations may properly contact or communicate with your patient advocacy functional personnel?
  • Please estimate the number of FTEs within your organization dedicated to patient advocacy activities
  • How many years of experience do you have working on patient advocacy objectives?
  • How many patient advocacy groups do you support or plan to support in the coming year?

SAMPLE KEY FINDINGS
  • Steady rise in the number of advocacy groups supported by companies: Participating companies predict an increase in the number of external advocacy groups that their organization supports. Currently companies support an average of 23 advocacy groups. In the next two years, participants estimated they will support, on average, 29 patient advocacy groups. Meanwhile, companies have about 5 FTE in their patient advocacy groups, on average. These employees have more than 10 years of advocacy experience, on average.

METHODOLOGY

Best Practices, LLC engaged 48 leaders supporting patient advocacy initiatives at 43 biopharmaceutical companies in the United States through a benchmarking survey.


Industries Profiled:
Biopharmaceutical; Biotech; Communications; Pharmaceutical; Medical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Acceleron Pharma; Agendia; Alnylam Pharmaceuticals; Amicus Therapeutics; ApotheCom; Astellas; AveXis; AVROBIO; Baldwin Area Medical Center; Bayer; Biogen; Blue Earth Diagnostics; Boehringer Ingelheim; CRISPR Therapeutics; Daiichi Sankyo; Dermira; Forum Pharmaceuticals; Grifols; GlaxoSmithKline ; Genzyme; Horizon Pharma; Incyte; Ipsen; Janssen; Johnson & Johnson; Lexicon Pharmaceuticals; Mallinckrodt; Milestone Pharmaceuticals; Natera; Novartis; Novo Nordisk; OTSUKA; Pfizer; Pharmacyclics; Reata Pharmaceuticals; Retrophin; Sage Therapeutics; Spark Therapeutics; Theravance; Ultragenyx; Wave Life Sciences; Zimmer Biomet; Zogenix

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.